ToffCap’s Monday Monitor #75Keros Therapeutics, Inc. – KROS
Pitch Summary: Keros Therapeutics has initiated a capital return program, including a $375 million cash return to shareholders, following a strategic review. BSD Analysis: Keros Therapeutics’ decision to return $375 million to shareholders, representing a significant portion of its market cap, reflects the outcome of its strategic review. The tender offer at $17.75 per share […]
